Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 86.77M | 67.46M | 59.95M | 49.32M | 73.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.77M | 67.46M | 59.95M | 49.32M | 73.69M |
| Cost of Revenue | 43.11M | 38.48M | 56.66M | 49.74M | 37.79M |
| Gross Profit | 43.66M | 28.98M | 3.29M | -417.00K | 35.91M |
| SG&A Expenses | 36.40M | 34.56M | 37.70M | 43.93M | 42.32M |
| Depreciation & Amortization | 9.52M | 9.01M | -- | -- | 9.15M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.23M | 157.21M | 173.73M | 170.55M | 160.27M |
| Operating Income | -73.46M | -89.76M | -113.77M | -121.22M | -86.58M |
| Income Before Tax | -71.72M | -93.66M | -109.67M | -118.00M | -77.00M |
| Income Tax Expenses | 184.00K | -2.41M | 1.99M | -1.84M | 1.56M |
| Earnings from Continuing Operations | -71.90M | -91.25M | -111.66M | -116.16M | -78.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.90M | -91.25M | -111.66M | -116.16M | -78.56M |
| EBIT | -73.46M | -89.76M | -113.77M | -121.22M | -86.58M |
| EBITDA | -63.53M | -81.00M | -104.71M | -113.03M | -72.58M |
| EPS Basic | -0.18 | -0.25 | -0.33 | -0.36 | -0.26 |
| Normalized Basic EPS | -0.10 | -0.15 | -0.20 | -0.23 | -0.15 |
| EPS Diluted | -0.18 | -0.25 | -0.33 | -0.36 | -0.26 |
| Normalized Diluted EPS | -0.10 | -0.15 | -0.20 | -0.23 | -0.15 |
| Average Basic Shares Outstanding | 406.97M | 364.04M | 334.51M | 322.87M | 304.89M |
| Average Diluted Shares Outstanding | 406.97M | 364.04M | 334.51M | 322.87M | 304.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |